<DOC>
	<DOC>NCT02516046</DOC>
	<brief_summary>This study is designed to test the relationship between ante-mortem 18F-AV-1451 Positron Emission Tomography (PET) imaging and tau neurofibrillary pathology associated with Alzheimer's disease (AD), as measured at autopsy.</brief_summary>
	<brief_title>18F-AV-1451 Autopsy Study</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Have a projected life expectancy of â‰¤ 6 months Can tolerate a 20 minute PET scan Give informed consent or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the State in which they die Aggressively being treated with life sustaining measures Known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment Clinically significant infectious disease Currently receiving any investigational medications except with permission from the study sponsor Participated in an experimental study with an amyloid or tau targeting agent Suspected encephalopathy due to alcoholism or endstage liver disease Females of childbearing potential History of risk factors for Torsades de Pointes or are currently taking medication known to cause QT prolongation</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>